ASCO: BMS’s Mezigdomide More Than Doubles PFS In Relapsed/Refractory Myeloma - Citeline News & In...

ASCO: BMS’s Mezigdomide More Than Doubles PFS In Relapsed/Refractory Myeloma  Citeline News & Insights

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospectiv...

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma  Nature

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple...

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple Myeloma Receiving a Lenalidomide-Based Induction Regimen  Journal of Hematology Oncology Pharmacy

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-...

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma  The ASCO Post

AUGMENT phase III 5-year follow-up: Lenalidomide + rituximab in R/R iNHL - Lymphoma Hub

AUGMENT phase III 5-year follow-up: Lenalidomide + rituximab in R/R iNHL  Lymphoma Hub

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refrac...

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial  The Lancet

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL - OncLive

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL  OncLive

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma - Targeted Oncology

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma  Targeted Oncology

Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapie...

Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapies  PR Newswire

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a ra...

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial  Nature

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): ...

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial  The Lancet

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma...

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma  The ASCO Post

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in ...

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma  OncLive

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple My...

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma  The ASCO Post

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: A...

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses | Blood Cancer Journal  Nature

Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma - OncLive

Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma  OncLive

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and...

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study | Leukemia  Nature

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

IRX4204 sensitizes multiple myeloma to ferroptosis and improves lenalidomide efficacy through the...

IRX4204 sensitizes multiple myeloma to ferroptosis and improves lenalidomide efficacy through the HMOX1-GPX4 axis  Nature

Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell...

Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma  Frontiers

Isatuximab Plus Lenalidomide, Bortezomib, and Dexamethasone (Isa-RVd) as Induction Therapy in Tra...

Isatuximab Plus Lenalidomide, Bortezomib, and Dexamethasone (Isa-RVd) as Induction Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Primary Analysis of Parallel Phase 2 Studies by the Dana-Farber Cancer Institute (DFCI)  OncLive

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma - ...

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma  OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma - OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma  OncLive

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/...

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line ...

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line  AJMC

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions ...

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma  OncLive

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

5-Year AUGMENT Data Support Lenalidomide Plus Rituximab in R/R iNHL - Clinical Oncology News

5-Year AUGMENT Data Support Lenalidomide Plus Rituximab in R/R iNHL  Clinical Oncology News

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Dia...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma  OncLive

Tafasitamab + rituximab + lenalidomide approved by Australia’s TGA for R/R FL - Lymphoma Hub

Tafasitamab + rituximab + lenalidomide approved by Australia’s TGA for R/R FL  Lymphoma Hub

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM - Hematology A...

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM  Hematology Advisor

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma - OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma  OncLive

Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1 - Pharmacy Times

Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1  Pharmacy Times

Role of Dual Maintenance Remains Uncertain in Multiple Myeloma - Targeted Oncology

Role of Dual Maintenance Remains Uncertain in Multiple Myeloma  Targeted Oncology

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma...

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma  OncLive

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results - Lymphoma Hub

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results  Lymphoma Hub

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple My...

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma  Cureus

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalid...

Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)  OncLive

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma - O...

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma  OncLive

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL - Lymphoma Hub

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL  Lymphoma Hub

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, New...

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma  OncLive

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory ...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with rela...

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with relapsed/refractory multiple myeloma — Polish early real-world experience following DRd reimbursement in the B.54 drug program | Piotrowska | Acta Hae  Via Medica Journals

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly D...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma  OncLive

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide ...

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide  Pharmacy Times

Some Frail Myeloma Patients Can Quickly Wean Off Dexamethasone, Study Says - MedPage Today

Some Frail Myeloma Patients Can Quickly Wean Off Dexamethasone, Study Says  MedPage Today

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myel...

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma  Pharmacy Times

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma - OncLive

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma  OncLive

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rit...

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL  Pharmacy Times

ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) ...

ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL  Lymphoma Hub

Al-Ola Abdallah: A Breakthrough Phase 3 Trial Reshaping Post-Lenalidomide Treatment - Oncodaily

Al-Ola Abdallah: A Breakthrough Phase 3 Trial Reshaping Post-Lenalidomide Treatment  Oncodaily

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-D...

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-DRd in Italy: A Multi-Criteria Decision Framework  EMJ

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety - Pharm...

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety  Pharmacy Times

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Mye...

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study  OncLive

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Lenalidomide Erectile Dysfunction: Understanding the Connection and Practical Management Options ...

Lenalidomide Erectile Dysfunction: Understanding the Connection and Practical Management Options  Portal CNJ

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England J...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules - Lupin | Press Release - lupin.com

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules - Lupin | Press Release  lupin.com

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradat...

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation  Nature

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphom...

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide -...

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide  Nature

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - AJMC

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  AJMC

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma:...

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial  Nature

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma - The New England Journal ...

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma  The New England Journal of Medicine

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients - ERS - Eu...

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients  ERS - European Respiratory Society

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL - Lymphoma Hub

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL  Lymphoma Hub

The 10 Lenalidomide Side Effects You Should Know About - GoodRx

The 10 Lenalidomide Side Effects You Should Know About  GoodRx

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (...

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma | Blood Cancer Journal  Nature

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America - The New England ...

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America  The New England Journal of Medicine

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma - The New England Jo...

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma  The New England Journal of Medicine

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-...

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial  Nature

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial  Nature

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma  Nature

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomi...

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma  Nature

Lenalidomide long-term neurotoxicity - Neurology® Journals

Lenalidomide long-term neurotoxicity  Neurology® Journals

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma - The New England Jour...

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma  The New England Journal of Medicine

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using ...

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4  Nature

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q)...

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS  OncLive

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in ...

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)  Nature

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England Journal of ...

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules - Docwire News

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules  Docwire News

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma - Onc...

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma  OncLive

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide | Cancer Gene Therap...

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide | Cancer Gene Therapy  Nature

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England Journal of Me...

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide - Science | AAAS

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide  Science | AAAS

Using Lenalidomide and Pomalidomide in RRMM Management - AJMC

Using Lenalidomide and Pomalidomide in RRMM Management  AJMC